Trials / Completed
CompletedNCT00686088
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sophiris Bio Corp · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate. Therapeutic activity will be determined based on changes in PSA levels, PSA velocity, PSA doubling time and tumor burden following treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRX302 | Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-05-29
- Last updated
- 2009-10-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00686088. Inclusion in this directory is not an endorsement.